Hot flashes, a subjective feeling of heat that is associated with objective signs of vasodilation and a drop in core temperature, are a distressing symptom of cancer treatment. Hot flashes are a side effect of estrogen deprivation in women treated for hormone-sensitive cancers; they occur with varying intensity and frequency and affect more than 90% of women with breast cancer, especially those with ovarian suppression added to tamoxifen or aromatase inhibitors. The pathophysiology of this phenomenon is not well understood but dysregulation in the hypothalamus as well as neurotransmitter involvement are thought to be important. The Hot Flash Related Daily Interference Scale contains 10 items that measure interference on daily life during the past week on a scale from 0 to 10. There are a number of evidence-based interventions that have been shown to reduce the frequency of hot flashes in women.